Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes
NCT00577824Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2008
- Primary completion
- Nov 2008
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of exenatide in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by AstraZeneca. Primary endpoint: Change in Glycosylated Hemoglobin (HbA1c) at 24 weeks. Started Jan 2008; status: completed.
02
Drugs
exenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00577824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00577824.